Peptides comprising non-natural amino acids and methods of making and using the same

• US 9,789,164 B2
• Filed: 03/17/2014
• Issued: 10/17/2017
• Est. Priority Date: 03/15/2013
• Status: Active Grant

• Current Assignee: Longevity Biotech, Inc.
• Original Assignee: Longevity Biotech, Inc.
• Inventors: Shandler, Scott, Gellman, Samuel H., Gledhill, John M.
• Primary Examiner(s): Skowronek, Karlheinz R
• Assistant Examiner(s): NIEBAUER, RONALD T
• Application Number:
  US14/776,566
• Publication Number:
  US 20160045572A1
• Time in Patent Office: 1,310 Days
• Field of Search: None
• CPC Class Codes: A61J 1/00 Containers specially adapted for medical or pharmaceutical purposes capsules or the like for oral use A61J3/07; specially adapted for surgical or diagnostic appliances or instruments A61B50/30; containers for radioactive substances G21F5/00
• CPC Class Codes: A61K 38/2278 Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
• CPC Class Codes: C07K 14/57563 Vasoactive intestinal peptide [VIP]; Related peptides
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
• CPC Class Codes: G01N 2500/10 involving cells
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Abstract

This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.

Claims

1. A peptide comprising SEQ ID NO:

18.

2. The peptide of claim 1 wherein the peptide further comprises a primary amide at the C-terminus.

3. The peptide of claim 1, wherein the peptide further comprises an acetyl group at the N-terminus and a primary amide at the C-terminus.

4. A pharmaceutical composition, comprising:

(i) the peptide of claim 1, or a pharmaceutical salt derived therefrom; and

(ii) a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4, wherein the composition further comprises one other active agent.

6. A method of treating Parkinson'"'"'s Disease in a subject suffering from Parkinson'"'"'s Disease comprising administrating the pharmaceutical composition of claim 4.

7. A method of inhibiting secretion of TNF-α

in a subject comprising administering the pharmaceutical composition of claim 4 to a subject.

8. A kit comprising a first container comprising the pharmaceutical composition of claim 4.

9. The kit of claim 8, further comprising a second container comprising a vehicle for administration of the composition of claim 4.